Cytochrome P450 inhibitors and their method of use

1. A compound having formula (I):

including hydrates, solvates, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, wherein:

X and Y are each independently CH and connected by a double bond, or X and Y are each independently CH 2 and connected by a single bond;

R 1 is selected from a group consisting of Br,

R 2 is selected from a group consisting of hydrogen, hydroxyl, fluorine, and chlorine;

R 3 is selected from a group consisting of optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, optionally substituted 4-pyridyl, optionally substituted 1-imidazoyl, optionally substituted 2-imidazoyl, optionally substituted 4-imidazoyl, and CH 2 Oheteroaryl;

R 4 is selected from a group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 1-6 branched alkyl, optionally substituted C 3-7 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, COR 5 , C(O)OR 6 , C(O)NR 7a R 7b , SO 2 R 8 ,

A is selected from a group consisting of CH 2 ,

n is 0 or 1;

m is 1 or 2;

R 5 is selected from the group consisting of optionally substituted C 1-6 linear alkyl, optionally substituted C 1-6 branched alkyl, optionally substituted C 3-7 cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

R 6 is selected from the group consisting of optionally substituted C 1-6 linear alkyl, optionally substituted C 1-6 branched alkyl, and optionally substituted C 3-7 cycloalkyl;

R 7a and R 7b are each independently selected from a group consisting of hydrogen, optionally substituted C 1-6 linear alkyl, optionally substituted C 1-6 branched alkyl, and optionally substituted C 3-7 cycloalkyl;

R 8 is selected from the group consisting of optionally substituted C 1-6 linear alkyl, optionally substituted C 1-6 branched alkyl, optionally substituted C 3-7 cycloalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted aryl, optionally substituted C 3-7 heterocyclyl, and optionally substituted heteroaryl;

R 9a and R 9b are each independently selected from a group consisting of hydrogen, optionally substituted C 1-6 linear alkyl, optionally substituted C 1-6 branched alkyl, optionally substituted aryl, optionally substituted benzyl, —CH 2 OR 6 , —CH 2 SR 6 , and CH 2 heteroaryl;

R 10 is selected from the group consisting of optionally substituted C 1-6 linear alkyl, optionally substituted C 1-6 branched alkyl, and optionally substituted C 3-7 cycloalkyl; and

R 11a and R 11b are each independently selected from a group consisting of hydrogen and optionally substituted C 1-6 linear alkyl.

2. A compound selected from the group consisting of:

(E)-1-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(3-(trifluoromethoxy)phenylsulfonyl)piperazine;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(3-chloropropylsulfonyl)piperazine;

(E)-3-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazin-1-ylsulfonyl)benzonitrile;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(4-chloro-3-nitrophenylsulfonyl)piperazine;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(3-nitrophenylsulfonyl)piperazine;

(E)-1-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-hydroxystyryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(1H-imidazol-4-ylsulfonyl)piperazine;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(cyclopropylsulfonyl)piperazine;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(ethylsulfonyl) piperazine;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(isopropylsulfonyl) piperazine;

(E)-1-(4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazin-1-yl)(pyridin-3-yl)methanone;

(E)-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazin-1-yl)(3-nitrophenyl)methanone;

(E)-3-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazine-1-carbonyl)benzonitrile;

(E)-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazin-1-yl)(cyclopropyl)methanone;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(cyclopropylmethyl)piperazine;

(E)-ethyl 2-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazine-1-carboxamido)acetate;

(E)-1-(4-(3((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(pyridin-3-ylsulfonyl)piperazine;

(E)-3-((4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazin-1-yl)methyl)benzonitrile;

(E)-1-(4-(4-(3-chloro-5-((pyridin-3-yloxy)methyl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-4-(3-(4-bromostyryl)-5-fluorophenyl)pyridine;

(E)-4-(3-fluoro-5-(4-(pyridin-4-yl)styryl)phenyl)pyridine;

(E)-1-(4-(4-(3-fluoro-5-(pyridin-3-yl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(4-(3-chloro-5-(pyridin-3-ylmethyl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(4-(3-chloro-5-(1-hydroxy-2-methyl-1-(pyridin-3-yl)propyl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(4-(3-chloro-5-(2-methyl-1-(pyridin-3-yl)prop-1-enyl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(4-(3-chloro-5-(pyridin-4-yl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(4-(3-chloro-5-(pyridin-3-yl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)-4-(pyridin-3-ylsulfonyl)piperazine;

(E)-ethyl 2-(4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazine-1-carboxamido)acetate;

(E)-1-(cyclopropylsulfonyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazine;

(E)-1-(ethylsulfonyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazine;

(E)-1-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)-4-(trifluoromethylsulfonyl)piperazine;

1-(cyclopropylmethyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)piperazine;

4-(3-fluoro-5-(4-(pyridin-4-yl)phenethyl)phenyl)pyridine;

(E)-1-(3-(4-bromostyryl)-5-chlorophenyl)-1H-imidazole;

(E)-1-(4-(4-(3-chloro-5-(1H-imidazol-1-yl)styryl)phenyl)piperazin-1-yl)ethanone;

(E)-1-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)-4-(isopropylsulfonyl)piperazine;

1-(cyclopropylsulfonyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)piperazine;

1-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)-4-(isopropylsulfonyl)piperazine;

ethyl 2-(4-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)piperazine-1-carboxamido)acetate;

1-(ethylsulfonyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)piperazine;

1-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)-4-(trifluoromethylsulfonyl)piperazine;

1-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)-4-(pyridin-3-ylsulfonyl)piperazine;

(E)-1-(cyclopropylmethyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazine;

(E)-tert-butyl 1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperidin-4-ylcarbamate;

(E)-1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperidin-4-amine;

(E)-ethyl 2-(3-(1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperidin-4-yl)ureido)acetate;

(E)-tert-butyl 2-(4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazin-1-yl)-2-oxoacetate;

(E)-1-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazine;

1-(4-(4-(3-fluoro-5-(pyridin-4-yl)phenethyl)phenyl)piperazin-1-yl)ethanone;

1-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorophenethyl)phenyl)piperazin-1-yl)ethanone;

and pharmaceutically acceptable salts thereof.

3. A method of treating a subject having the disease diabetes mellitus, said method comprising administering to the subject an effective amount of at least one compound according to claim 1 to treat the disease.

4. The method of claim 3 , wherein the at least one compound is administered in a composition further comprising at least one excipient.

5. The compound of claim 1 wherein A is CH 2 and n is 0 or 1.

6. The compound of claim 1 wherein X and Y are each independently CH and connected by a double bond.

7. The compound of claim 6 wherein A is CH 2 and n is 1.

8. The compound of claim 6 wherein n is 0.

9. The compound of claim 8 wherein R 1 is

10. The compound of claim 1 wherein X and Y are each independently CH 2 and connected by a single bond.

11. The compound of claim 10 wherein A is CH 2 and n is 1.

12. The compound of claim 10 wherein n is 0.

13. The compound of claim 12 wherein R 1 is